The Trump administration gets a pro-life win

By Easton Martin | January 23, 2026

The Trump administration has ended federal funding for research that relies on tissue obtained from aborted fetuses, a move welcomed by pro life advocates as a long overdue correction in public policy.

For years, taxpayer dollars were routed toward research programs that depended on the remains of unborn children whose lives had already been ended through abortion. While defenders of the practice framed it as a scientific necessity, many Americans viewed it as a moral contradiction. A society that claims to value human dignity cannot ethically build medical progress on the destruction of its most vulnerable members.

By cutting off this funding, President Trump has drawn a clear ethical boundary. The decision affirms that medical innovation does not require the exploitation of aborted children and that scientific advancement and moral responsibility are not mutually exclusive. In fact, modern medicine has already demonstrated viable alternatives. Adult stem cells, umbilical cord blood, and induced pluripotent stem cells have produced real treatments without raising the same ethical concerns.

The administration’s action reinforces a foundational principle: human life has value at every stage, and government policy should reflect that truth. Ending support for fetal tissue research ensures that taxpayers are no longer compelled to underwrite practices they find morally objectionable.